Company: PTHS
Filing Date: 2025-05-13
Form Type: 10-Q
Source: 0001753926-25-000790
Chunk: 117

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-05-13
Form: 10-Q
Item: Part II, Item 1
Chunk 117
---
10.11
     
    First Amendment to Promissory Note dated May 12, 2025.

    31.1
     
    Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

    32.1
     
    Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

    101
     
    Interactive
    Data Files (embedded within the Inline XBRL document)

    104
     
    Cover
    Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

+
Indicates management contract or compensatory plan. 

In
accordance with SEC Release 33-8238, Exhibit 32.1 is being furnished and not filed.

40

SIGNATURES

Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.

    Channel
    Therapeutics Corporation

    Date:
    May 13, 2025
    By:
    /s/
    Francis Knuettel II

    Name:
    Francis Knuettel II

    Title:
Chief Executive Officer and President, Chief Financial Officer, Treasurer and Secretary 
        (Principal
Executive Officer, Principal Financial Officer, Principal Accounting Officer)

41